Want to see JP:4891 full AI Analyst Report?
4891 Stock Chart & Stats
¥129.00
-¥1.00(-0.47%)
At close: 4:00 PM EST
¥129.00
-¥1.00(-0.47%)
Day’s Range― - ―
52-Week Range¥92.00 - ¥166.00
Previous CloseN/A
Volume100.70K
Average Volume (3M)395.53K
Market Cap
¥6.06B
Enterprise Value¥2.51K
Total Cash (Recent Filing)¥3.18B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Apr 09, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.99
Shares Outstanding48,455,270
10 Day Avg. Volume581,420
30 Day Avg. Volume395,526
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-25.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of reported debt reduces leverage and interest-burden risk, giving TMS a more conservative financial structure than a highly indebted biotechnology company. This preserves some flexibility to direct resources toward operations, development, or future financing needs.
Historical Cash GenerationStrong positive operating and free cash flow in 2022 demonstrates that TMS has previously been capable of converting business activity into cash. Although this performance has not persisted, it provides evidence that cash generation is possible under favorable operating conditions.
Prior Commercial EarningsThe profitable 2022 period indicates that TMS has previously generated meaningful revenue and earnings rather than operating solely as a pre-commercial biotechnology business. That history offers a foundation for potential recovery if commercial activity can be re-established.
Bears Say
Persistent Losses And Limited RevenueSeveral consecutive years of deep operating and net losses, combined with effectively absent recent revenue, indicate that the current business model is not producing stable commercial income. This weakens earnings visibility and makes sustained operations dependent on a successful turnaround.
Ongoing Cash BurnRepeated negative operating and free cash flow shows that TMS is consuming cash rather than funding itself through operations. Persistent burn reduces financial flexibility and increases the importance of achieving profitability or obtaining additional external funding over the coming quarters.
Declining Equity BaseThe decline in equity from 2023 through 2025 suggests that continuing losses are eroding the company’s financial cushion. Even with no reported debt, a shrinking equity base can reduce resilience and leave fewer internally funded resources available for development and operations.
TMS Co., Ltd. News
4891 FAQ
What was TMS Co., Ltd.’s price range in the past 12 months?
TMS Co., Ltd. lowest stock price was ¥92.00 and its highest was ¥166.00 in the past 12 months.
What is TMS Co., Ltd.’s market cap?
TMS Co., Ltd.’s market cap is ¥6.06B.
When is TMS Co., Ltd.’s upcoming earnings report date?
TMS Co., Ltd.’s upcoming earnings report date is Apr 09, 2027 which is in 204 days.
How were TMS Co., Ltd.’s earnings last quarter?
TMS Co., Ltd. released its earnings results on Aug 14, 2026. The company reported -¥4.15 earnings per share for the quarter.
Is TMS Co., Ltd. overvalued?
According to Wall Street analysts TMS Co., Ltd.’s price is currently Overvalued.
Does TMS Co., Ltd. pay dividends?
TMS Co., Ltd. does not currently pay dividends.
What is TMS Co., Ltd.’s EPS estimate?
TMS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TMS Co., Ltd. have?
TMS Co., Ltd. has 48,455,270 shares outstanding.
What happened to TMS Co., Ltd.’s price movement after its last earnings report?
TMS Co., Ltd. reported an EPS of -¥4.15 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of TMS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4891
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TMS Co., Ltd.
Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.